2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Polymyalgia Rheumatica: new trials by email Literature Review of Polymyalgia Rheumatica trials Research Report on Polymyalgia Rheumatica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | Completed | Novartis Pharmaceuticals | 65 | 2024-03-27 | 2026-04-01 |
| A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) Prednisolone, SPI-62 - Polymyalgia Rheumatica | Phase 1 | Terminated | Sparrow Pharmaceuticals | 1 | 2022-02-22 | 2025-05-16 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Nivolumab - Autoimmune Diseases, Non-small Cell Lung Cancer | Phase 1 | Terminated | Alliance Foundation Trials, LLC. | 7 | 2019-06-27 | 2023-02-15 |
Giant Cell Arteritis (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Psoriasis (1)
Connective Tissue Diseases (3) · Muscular Diseases (3) · Musculoskeletal Diseases (3) · Rheumatic Diseases (3) · Skin and Connective Tissue Diseases (3) · Arteritis (2) · Autoimmune Diseases of the Nervous System (2) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Cerebrovascular Disorders (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2)
Nivolumab (1) · Prednisolone (1) · secukinumab (1)
Alliance Foundation Trials, LLC. (1) · Novartis Pharmaceuticals (1) · Sparrow Pharmaceuticals (1)
United States (2) · Czechia (1) · Germany (1) · Italy (1) · Portugal (1) · Spain (1) · Switzerland (1)
David Katz (1)
2023 (1)